Polynesia to Legalize CBD Followed by Medical Cannabis

Polynesia has announced plans to legalize CBD with a new article of legislation known as Article LP3. The legislation contains three key aspects: the legalization of CBD, new rules for the cultivation and processing of cannabis, and the introduction of medical cannabis. While the country has yet to publish many details, the complete bill is expected to be made public in the coming days.

After his first 100 days in office, Moetai Brotherson announced this week that the project to legalize CBD in Polynesia is ready. Polynesia also has possible medical cannabis legalization in the works, which is set to follow the rollout of its CBD legalization bill.

For more news like this, download our free cannabis news app.

The New Legal Framework for Polynesia

The bill, known as Article LP3, establishes an innovative framework for the use and importation of hemp in Polynesia.

Article LP3 allows the Polynesian population to “transport, import, export, hold, offer, transfer, acquire, process, and use products containing or derived from hemp seeds.”

These products must be “devoid of intoxicating properties,” meaning that, for the moment, their THC content must be below 0.3%.

Challenges in Meeting THC Guidelines

Despite the tropical climate in Polynesia, cannabis plants nonetheless produce an explosion of phytocannabinoids, making it challenging for the local industry to maintain the 0.3% THC threshold set by French standards.

Under the initiative of its president, Philippe Cathelain, the Polynesian Cannabis Syndicate has advocated for this threshold to be increased to 1%, taking into account local conditions.

This recommendation comes from a French National Assembly information mission, which stressed the need for tolerance in overseas territories like Polynesia, as is already the case for Réunion.

The Three Key Aspects of the New Legislation

This new legislation for Polynesia has three essential components.

In addition to legalizing CBD, the Ministry of Agriculture has drafted a second text concerning the cultivation and processing of cannabis.

But the most anticipated aspect is the third one, related to medical cannabis in Polynesia. Beyond CBD’s anti-stress properties, healthcare professionals are particularly interested in THC’s pain-relief potential.

Medical Community in Polynesia Weighs In

Philippe Dupire, a pharmacist at the French Polynesia Hospital Center, emphasizes to TNTV that THC can be valuable for treating intractable pain and neurological diseases such as epilepsy.

However, the text specifies that products containing cannabis or cannabinoids can only be claimed to have therapeutic properties if they obtain authorization as medicines.

Currently, only three cannabis-based medications are available in mainland France, and this new legislation will allow their importation into Polynesia.

Exceptions for Certain Medications

The legislation provides exceptions for certain medications, allowing their use “on an exceptional basis” when “the implementation of the treatment is likely to benefit the patient” and when “the efficacy and safety of these medicines are strongly presumed based on current scientific knowledge.” 

The Polynesia Council of Ministers will compile a list of these exceptional medicines, which will likely include cannabis extracts and flowers.

Full Bill to Be Disclosed By Polynesia Soon

For now, the bill is yet to be made public. However, its release by Polynesia is expected to be made in the “coming days.”

—

(Featured image by Damien Chaudet via Unsplash)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.